Swissmedic Highlights Post-Market Surveillance Obligations for Legacy Devices
Swissmedic, the Swiss Agency for Therapeutic Products, has released findings from a recent focused action, underscoring the critical importance of robust Post-Market Surveillance (PMS) for all medical devices, including those classified as Legacy Devices (LDs). The review emphasizes that manufacturers must actively monitor the performance and safety of their devices throughout their lifecycle.
MedNet EC-REP
Author
The Swissmedic review focused on Periodic Safety Update Reports (PSURs). These reports are crucial for proactively identifying potential risks and ensuring continued device safety and effectiveness.
Key Findings and Implications
The Swissmedic review highlighted several key areas needing improvement among manufacturers. While the specific details of these shortcomings are outlined in the full Swissmedic report, the agency is using the review to remind manufacturers of their obligations.
EU and Swiss Regulations Demand PMS for Legacy Devices
The announcement serves as a timely reminder that both European Union (EU) regulations and Swiss regulations require manufacturers to meet comprehensive PMS requirements for Legacy Devices. Despite these devices being on the market for some time, manufacturers are not exempt from the responsibility of actively monitoring their safety and performance. This includes:
- Systematic data collection: Gathering data from various sources, including user feedback, complaints, and scientific literature.
- Proactive risk assessment: Regularly evaluating potential risks associated with the device and taking appropriate corrective actions.
- Transparent reporting: Submitting timely and accurate PSURs to regulatory authorities.
Manufacturers who fail to meet these PMS requirements risk facing regulatory action, including device recalls and market withdrawals. Swissmedic emphasizes its commitment to ensuring patient safety and will continue to actively monitor compliance with PMS regulations.
Link to the Swissmedic Report: EN_Schwerpunktaktion_PSUR-final.pdf
Related Articles
Well-Established Technologies Under the MDR: EU Commission Expands Exemption List
The EU Commission has expanded the WET list under the MDR, easing requirements for certain class II and class III devices.
MHRA Device Registration: New Clarification on "Placing on the Market" and "Putting into Service" (Update 20 July 2026)
MHRA clarifies medical device registration: 20 July 2026 update explains "placing on the market" vs. "putting into service" in GB.
EC REP Becomes EU REP: What the New Authorised Representative Symbol Means for Medical Device Manufacturers
In short: On 17 June 2026, the European Commission published the reference of EN ISO 15223-1:2021/A1:2025 in the Official Journal of the European Union (OJEU) for both the MDR and the IVDR. This amendment replaces the long-standing "EC REP" symbol with "EU REP" for the authorised representative in the European Union. The change is purely editorial, and you have a five-year transition period - until 17 June 2031 - during which both symbols remain valid.
Stay Updated
Get the latest regulatory updates and industry insights delivered to your inbox.
Subscribe to Updates